Bioventus Stabilizes, Assesses Path Forward

Bioventus reported 2Q23 orthopedic sales of $117.4 million, -1.9% compared to the second quarter of 2022. The company generated $224.9 million in orthopedic sales in the first half of 2023, -1.3% compared to the first half of 2022.

Through the first half of the year, the company significantly improved its financial position with adjusted...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us